Literature DB >> 18824264

Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression.

S Peter Bak1, Anselmo Alonso, Mary Jo Turk, Brent Berwin.   

Abstract

The predominant leukocyte population present in both human and murine peritoneal ovarian tumors is the Vascular Leukocyte (VLC). VLCs are recruited en masse to the ovarian tumor microenvironment whereupon they promote tumor progression. Importantly, the presence of VLCs is requisite for peritoneal ovarian cancer progression: selective elimination of VLCs inhibits tumor burden and ascites accumulation. Despite the critical importance of VLCs to ovarian tumors, their derivation and the mechanisms by which they facilitate tumor progression are not well understood. Here we demonstrate in vivo that the murine ID8 ovarian tumor model can usurp the host peritoneal macrophage pathway to elicit and recruit VLCs. Moreover, we demonstrate that VLCs express CD11b and Gr-1, a characteristic phenotype shared amongst heterogeneous populations of leukocytes referred to as myeloid-derived suppressor cells (MDSCs). In accord with their MDSC phenotype, both murine and human VLCs express arginase-1 (ARG1). Importantly, we demonstrate that the VLCs suppress both CD8(+) and CD4(+) T cells responses and that this immunosuppression is ARG1-dependent, since blockade of VLC ARG1 activity with nor-NOHA reversed the immunosuppression. These data further characterize the tumor-associated leukocytes in ovarian cancer and provide insights into the mechanisms by which they promote tumor growth.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18824264      PMCID: PMC2613193          DOI: 10.1016/j.molimm.2008.08.266

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  52 in total

1.  Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells.

Authors:  V Bronte; E Apolloni; A Cabrelle; R Ronca; P Serafini; P Zamboni; N P Restifo; P Zanovello
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

2.  Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis.

Authors:  Li Yang; Laura M DeBusk; Koari Fukuda; Barbara Fingleton; Brenda Green-Jarvis; Yu Shyr; Lynn M Matrisian; David P Carbone; P Charles Lin
Journal:  Cancer Cell       Date:  2004-10       Impact factor: 31.743

Review 3.  Derangement of immune responses by myeloid suppressor cells.

Authors:  Paolo Serafini; Carmela De Santo; Ilaria Marigo; Sara Cingarlini; Luigi Dolcetti; Giovanna Gallina; Paola Zanovello; Vincenzo Bronte
Journal:  Cancer Immunol Immunother       Date:  2003-10-30       Impact factor: 6.968

4.  Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A.

Authors:  Jose R Conejo-Garcia; Fabian Benencia; Maria-Cecilia Courreges; Eugene Kang; Alisha Mohamed-Hadley; Ronald J Buckanovich; David O Holtz; Ann Jenkins; Hana Na; Lin Zhang; Daniel S Wagner; Dionyssios Katsaros; Richard Caroll; George Coukos
Journal:  Nat Med       Date:  2004-08-29       Impact factor: 53.440

5.  Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma.

Authors:  Mary Jo Turk; David J Waters; Philip S Low
Journal:  Cancer Lett       Date:  2004-09-30       Impact factor: 8.679

6.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

7.  Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses.

Authors:  Paulo C Rodriguez; David G Quiceno; Jovanny Zabaleta; Blair Ortiz; Arnold H Zea; Maria B Piazuelo; Alberto Delgado; Pelayo Correa; Jason Brayer; Eduardo M Sotomayor; Scott Antonia; Juan B Ochoa; Augusto C Ochoa
Journal:  Cancer Res       Date:  2004-08-15       Impact factor: 12.701

8.  Translational control of inducible nitric oxide synthase by IL-13 and arginine availability in inflammatory macrophages.

Authors:  Stefan El-Gayar; Heike Thüring-Nahler; Josef Pfeilschifter; Martin Röllinghoff; Christian Bogdan
Journal:  J Immunol       Date:  2003-11-01       Impact factor: 5.422

9.  Conditional macrophage ablation in transgenic mice expressing a Fas-based suicide gene.

Authors:  Sandra H Burnett; Edward J Kershen; Jiayou Zhang; Li Zeng; Susan C Straley; Alan M Kaplan; Donald A Cohen
Journal:  J Leukoc Biol       Date:  2004-01-14       Impact factor: 4.962

10.  L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes.

Authors:  Paulo C Rodriguez; Arnold H Zea; Joanna DeSalvo; Kirk S Culotta; Jovanny Zabaleta; David G Quiceno; Juan B Ochoa; Augusto C Ochoa
Journal:  J Immunol       Date:  2003-08-01       Impact factor: 5.422

View more
  37 in total

1.  Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells.

Authors:  Melissa G Lechner; Daniel J Liebertz; Alan L Epstein
Journal:  J Immunol       Date:  2010-07-19       Impact factor: 5.422

2.  Myeloid-derived suppressor cells in murine AIDS inhibit B-cell responses in part via soluble mediators including reactive oxygen and nitrogen species, and TGF-β.

Authors:  Jessica L Rastad; William R Green
Journal:  Virology       Date:  2016-09-12       Impact factor: 3.616

3.  Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and Extent.

Authors:  Trevor E Angell; Melissa G Lechner; Alison M Smith; Sue E Martin; Susan G Groshen; Dennis R Maceri; Peter A Singer; Alan L Epstein
Journal:  Thyroid       Date:  2016-02-10       Impact factor: 6.568

Review 4.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

Review 5.  Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes.

Authors:  Juan R Cubillos-Ruiz; Melanie Rutkowski; Jose R Conejo-Garcia
Journal:  Cell Cycle       Date:  2010-01-26       Impact factor: 4.534

6.  Expression quantitative trait loci and receptor pharmacology implicate Arg1 and the GABA-A receptor as therapeutic targets in neuroblastoma.

Authors:  Christopher S Hackett; David A Quigley; Robyn A Wong; Justin Chen; Christine Cheng; Young K Song; Jun S Wei; Ludmila Pawlikowska; Yun Bao; David D Goldenberg; Kim Nguyen; W Clay Gustafson; Sundari K Rallapalli; Yoon-Jae Cho; James M Cook; Serguei Kozlov; Jian-Hua Mao; Terry Van Dyke; Pui-Yan Kwok; Javed Khan; Allan Balmain; QiWen Fan; William A Weiss
Journal:  Cell Rep       Date:  2014-10-23       Impact factor: 9.423

7.  Immunosuppressive mechanisms of regulatory dendritic cells in cancer.

Authors:  Galina V Shurin; Yang Ma; Michael R Shurin
Journal:  Cancer Microenviron       Date:  2013-06-09

8.  Myeloid-derived suppressor cells in murine retrovirus-induced AIDS inhibit T- and B-cell responses in vitro that are used to define the immunodeficiency.

Authors:  Kathy A Green; W James Cook; William R Green
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

9.  Ovarian tumor-induced T cell suppression is alleviated by vascular leukocyte depletion.

Authors:  S Peter; G Bak; Kevin Hart; Brent Berwin
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

10.  Preemptive donor apoptotic cell infusions induce IFN-γ-producing myeloid-derived suppressor cells for cardiac allograft protection.

Authors:  Jane Bryant; Nadine M Lerret; Jiao-Jing Wang; Hee-Kap Kang; James Tasch; Zheng Zhang; Xunrong Luo
Journal:  J Immunol       Date:  2014-05-07       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.